Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Leading small molecules for the selective protein clearance in ER disorders

Cel

Many severe genetic and age-related diseases are driven by the accumulation of misfolded proteins within the endoplasmic reticulum, leading to chronic cellular stress, tissue damage and organ failure. Despite major advances in targeted protein degradation, no current technology can selectively eliminate toxic proteins residing inside this cellular compartment. As a result, patients affected by the so-called ER-storage diseases (e.g. collagenopathies, corneal dystrophies or serpinopathies) still lack therapies that address the root cause of their condition.

Building on discoveries from the ERC AUTO-SELECT project, this Proof of Concept aims to translate the identification of ER-phagy as a selective, mutation-agnostic ER quality-control pathway into a therapeutic strategy. The project will develop and validate small molecules selectively activating ER-phagy and promoting the removal of disease-causing proteins without inducing global autophagy. This represents a first-in-class approach to degrade toxic ER-resident proteins that are inaccessible to existing modalities.

The PoC will confirm mechanism of action, demonstrate clearance of pathogenic proteins in validated disease models, and assess selectivity and cellular safety. In parallel, intellectual property will be consolidated within a dedicated spin-out, Eracle Bio, and aligned with a structured partnering and licensing strategy supported by an experienced life sciences investor. By delivering validated lead compounds and a partnering-ready data package, the project creates a clear pathway from ERC-funded discovery to industrial collaboration and clinical translation.

If successful, this work will establish a new therapeutic paradigm focused on compartment-specific protein degradation and open scalable opportunities for treating multiple currently untreatable diseases, with significant impact for both science and society.

Dziedzina nauki (EuroSciVoc)

Projekt nie został jeszcze sklasyfikowany według klasyfikacji EuroSciVoc.
Wskaż dziedziny nauki, które twoim zdaniem są najbardziej istotne z punktu widzenia tego projektu i pomóż nam usprawnić naszą usługę klasyfikacji.

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2026-POC

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

FONDAZIONE TELETHON ETS
Wkład UE netto
€ 150 000,00
Koszt całkowity
Brak danych

Beneficjenci (1)